The First Affiliated Hospital of Soochow University: all 258 studies

Page 2 of 3. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.

• Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal InvolvementRecruitingNCT06066840Phase 4
• Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological MalignanciesRecruitingNCT06041815
• Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGSRecruitingNCT06021210Phase 2
• VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingNCT05939180Phase 2/3
• A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLNot yet recruitingNCT05931757Phase 2
• TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological DiseasesRecruitingNCT05929092Not applicable
• The Relationship Between Self-disclosure, Perceived Social Support and Reproductive ConcernsRecruitingNCT05914181
• The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT05907486Phase 3
• Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma PatientsRecruitingNCT05855122Phase 4
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
• Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL PatientsRecruitingNCT05823701Phase 2
• CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
• Avapritinib in CBF-AML With KIT MutationsRecruitingNCT05821738Phase 2
• Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTRecruitingNCT05809167Phase 2
• Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
• Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNCT05805072Not applicable
• PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNCT05772273Not applicable
• ThisCART19A for B-NHL Relapsed After Auto-CAR TRecruitingNCT05691153Phase 1
• ThisCART19A Bridging to alloHSCT for R/R B-ALLRecruitingNCT05679687Phase 1
• Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCTNot yet recruitingNCT05669079Phase 3
• CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Not applicable
• CAV Regimen for R/R AMLRecruitingNCT05657639Phase 2
• Construction of a Database for TMARecruitingNCT05634928
• Construction of a Database for TTPRecruitingNCT05571774
• Aspirin for Prophylaxis of TTPNot yet recruitingNCT05568147Phase 2/3
• Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic LeukemiaRecruitingNCT05566054Phase 2
• Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT05561049
• Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLRecruitingNCT05559450Phase 2
• Olverembatinib for FGFR1-rearranged NeoplasmsRecruitingNCT05521204Phase 2
• GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCTRecruitingNCT05510505Phase 2
• Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
• Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
• AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionRecruitingNCT05404906Phase 2/3
• Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL PatientsRecruitingNCT05376111Phase 2
• Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
• AZA Combined With NAC for PIT After HSCTNot yet recruitingNCT05126004Phase 2
• Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05023707Phase 1/2
• Outcomes of Patients After Allo-HSCT With Decitabine and NACNot yet recruitingNCT04945096Phase 3
• Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLRecruitingNCT04835870Phase 2
• Efficacy and Safety of Auto-FMT in Preventing aGVHDRecruitingNCT04745221Not applicable
• Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT04739826
• Relationship Between "FODMAPs" and "GVHD"RecruitingNCT04660487
• Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）RecruitingNCT04534634Phase 2
• Follow-up Study of ICUS and CCUS PatientsEnrolling by invitationNCT04428489
• Nutritional Status of Patients After Hematopoietic Stem Cell TransplantationRecruitingNCT04146870
• Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Phase 1/2
• Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple MyelomaRecruitingNCT03196414Phase 1/2
• FMT in Gut aGVHD TreatedRecruitingNCT03148743
• Decitabine for Poor Graft Function Post Allo-HSCTCompletedNCT05907499Phase 3Results posted
• A Safety and Efficacy Study of NAC in Patients With TA-TMACompletedNCT03252925Phase 3Results posted
• Prospective Study of Patients With Thrombocytopenia Following HSCTCompletedNCT02487563Phase 3Results posted
• PDCA-Based Precision Nursing for Stroke Patients With TracheostomyCompletedNCT07687342Not applicable
• eCASH and Early Goal-Directed Mobilization to Prevent ICU-Acquired WeaknessCompletedNCT07677488Not applicable
• Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT07621406Phase 2
• Clinical Study of PRP in the Treatment of Androgenetic AlopeciaCompletedNCT07551271Not applicable
• N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic MicroangiopathyActive, not recruitingNCT07279610Phase 2/3
• Generation of Reactive T Cells Based on Tumor Whole Cell Antigen NanovaccinesActive, not recruitingNCT07239544
• Sequential CD19/CD22 CAR-T Cell Therapy Following ASCTCompletedNCT07236151Phase 2
• A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma PatientsCompletedNCT07206810
• Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALLSuspendedNCT06985498Phase 2
• A Clinical Study Comparing the Effectiveness and Safety of Two Surgical Pathways for Laparoscopic Total HysterectomyCompletedNCT06817460Not applicable
• Repeated Transcranial Magnetic Stimulation Relieves Maternal Care ImpairmentCompletedNCT06743724Not applicable
• Evaluation of CMV/EBV-CMI in Haploid HSCTStatus unknownNCT06554197
• Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLActive, not recruitingNCT06429098Phase 2
• Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With DiarrheaCompletedNCT06409078Not applicable
• Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's LymphomaTerminatedNCT06381830Phase 2
• Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) PatientsActive, not recruitingNCT06379360Phase 2
• Cohort Construction and Prognostic Model Construction for Multiple MyelomaActive, not recruitingNCT06366802
• Deep Learning in Classifying Bowel Obstruction RadiographsActive, not recruitingNCT06321614
• The Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP PancreatitisCompletedNCT06031363Not applicable
• A Registry for Patients With Systemic Mastocytosis in ChinaStatus unknownNCT06013683
• An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaWithdrawnNCT05980507Phase 1
• Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus unknownNCT05951855Phase 2
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in ChinaCompletedNCT05789615
• Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTRStatus unknownNCT05761457Not applicable
• M-PTCy vs BuCy in Haploidentical HSCT for Acute LeukemiaStatus unknownNCT05739630Phase 2/3
• Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AMLCompletedNCT05654194Phase 3
• Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell TransplantationStatus unknownNCT05634915Phase 4
• Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell TransplantationWithdrawnNCT05587881
• Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownNCT05578378Phase 2/3
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2
• This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.Status unknownNCT05486975Early Phase 1
• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLActive, not recruitingNCT05470777Phase 2
• The Use of Eltrombopag Post HSCT in BMFDCompletedNCT05466201Phase 2/3
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT05322330Phase 2
• Anti-BCMA CAR T-Cell Therapy for R/R ITPStatus unknownNCT05315778Phase 2
• Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's LymphomaWithdrawnNCT05312476Phase 2
• Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in AdultsStatus unknownNCT05282719Phase 2
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#CompletedNCT05270928Phase 1
• Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After TransplantationStatus unknownNCT05266274Not applicable
• A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT05210946Not applicable
• Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal FloraStatus unknownNCT05199649Not applicable
• CAV Regimen Bridging to HSCT for R/R ALCompletedNCT05190549Phase 2
• PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t CellsStatus unknownNCT05176275Not applicable
• Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDSStatus unknownNCT05175508Phase 2/3
• Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell CarcinomaStatus unknownNCT05174325Phase 2
• the Effect of Acupoint Application Combined With Ear Acupoint Embedding in Patients After Esophageal Cancer SurgeryStatus unknownNCT05151068Not applicable

← The First Affiliated Hospital of Soochow University overview and focus areas